NCT02181504 - A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Macular Degeneration

Interventions

DRUG

abicipar pegol

Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.

DRUG

ranibizumab

Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.

OTHER

sham procedure

Sham procedure to the study eye at weeks 12 and 16.

Trial Locations (11)

Nihon University Hospital, Chiyoda-ku,Tokyo

1 Fukushima Medical University, Fukushima

Kyushu University Hospital, Kita-ku, Fukuoka-shi Fukuoka

Okayama University Hospital, Kita-ku, Okayama-shi Okayama

Shiga University, Ōtsu

Tokyo Women's Medical University, Shinjuku-ku

Nagoya University Hospital, Showa-ku, Nagoya-shi Aichi

Takeuchi Eye Clinic, Taito Ku Tokyo

Musashi Dream Clinic, Tennoji-ku Osaka

Juntendo University Urayas, Urayasu-shi

Otakeganka Tsukimino Clinic, Yamato Kanagawa